The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The…
News
GYNECOLOGICAL CANCER
New targeted cancer therapy IDE034 heading to Phase 1 clinical trial
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start…
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SENTI-202, Senti Biosciences‘ experimental cell therapy being developed…
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH…
GYNECOLOGICAL CANCER
Dosing begins in trial testing Enhertu for ovarian cancer
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine CLN-049, which is being developed as a potential treatment…
PANCREATIC CANCER
Oncolytics to test immunotherapy against aggressive pancreatic cancer
Oncolytics Biotech has cleared a significant hurdle in the U.S. to advance its unique viral immunotherapy, pelareorep, to a pivotal Phase 3 trial for…
GYNECOLOGICAL CANCER
New therapy DT2216 tackles tough-to-treat ovarian cancer
A new experimental therapy, DT2216, has begun testing in a clinical trial for people with hard-to-treat ovarian cancer, a significant step forward announced by…
Most myeloma patients who started treatment at the Berenson Cancer Center — a clinic in California that specializes in myeloma care — lived…
Recent Posts
- The parallel calendars: Living between treatment cycles and ordinary days
- First participant receives GLIX1 in early glioblastoma clinical trial
- World Ovarian Cancer Day campaign spotlights scars seen and unseen
- Gilead completes Arcellx buy, securing myeloma treatment anito-cel
- Why the answer to ‘Should I call the doctor?’ is always yes
